Do analysts prefer ABVC or RFL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ABVC or RFL more profitable?

ABVC BioPharma has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -47.68% -30.97% Rafael -3,321.74% -41.27% -35.32%

Do analysts rate VANI or ABVC?

Vivani Medical currently has a consensus target price of $3.75, indicating a potential upside of 215.13%. Given Vivani Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe Vivani Medical is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivani Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VANI or ABVC more profitable?

ABVC BioPharma's return on equity of -47.68% beat Vivani Medical's return on equity. Company Net Margins Return on Equity Return on Assets Vivani Medical N/A -191.05% -70.91% ABVC BioPharma N/A -47.68% -30.97%

Do analysts prefer ABVC or AARD?

Aardvark Therapeutics has a consensus price target of $15.33, suggesting a potential upside of 185.01%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aardvark Therapeutics 2 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.42

Is ABVC or AARD more profitable?

ABVC BioPharma's return on equity of -47.68% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -47.68% -30.97% Aardvark Therapeutics N/A -71.54% -64.94%

Do analysts prefer ABVC or PLYX?

Polaryx Therapeutics has a consensus target price of $7.67, indicating a potential upside of 275.82%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Is ABVC or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -47.68% -30.97% Polaryx Therapeutics N/A N/A N/A

Do analysts rate CPIX or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

ABVC BioPharma (ABVC) Competitors

$1.16 +0.01 (+0.87%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.16 0.00 (-0.43%)

As of 09/18/2026 07:30 PM Eastern

Compare

ABVC vs. RFL, VANI, AARD, PLYX, and CPIX

Should you buy ABVC BioPharma stock or one of its competitors? ABVC BioPharma's main competitors and comparable companies include Rafael (RFL), Vivani Medical (VANI), Aardvark Therapeutics (AARD), Polaryx Therapeutics (PLYX), and Cumberland Pharmaceuticals (CPIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ABVC BioPharma compare to Rafael?

ABVC BioPharma (NASDAQ:ABVC) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

ABVC BioPharma has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Rafael	-3,321.74%	-41.27%	-35.32%

ABVC BioPharma has higher earnings, but lower revenue than Rafael. ABVC BioPharma is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	60.62	-$7.91M	-$0.30	N/A
Rafael	$920K	116.27	-$30.52M	-$0.68	N/A

11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 11.3% of Rafael shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by insiders. Comparatively, 32.9% of Rafael shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ABVC BioPharma has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Rafael has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

In the previous week, Rafael had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 1 mentions for Rafael and 0 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.00 equaled Rafael'saverage media sentiment score.

Company	Overall Sentiment
ABVC BioPharma	Neutral
Rafael	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

ABVC BioPharma and Rafael tied by winning 6 of the 12 factors compared between the two stocks.

How does ABVC BioPharma compare to Vivani Medical?

Vivani Medical (NASDAQ:VANI) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

Vivani Medical has a beta of 2.36, indicating that its share price is 136% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Vivani Medical currently has a consensus target price of $3.75, indicating a potential upside of 215.13%. Given Vivani Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe Vivani Medical is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Vivani Medical had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 1 mentions for Vivani Medical and 0 mentions for ABVC BioPharma. Vivani Medical's average media sentiment score of 1.05 beat ABVC BioPharma's score of 0.00 indicating that Vivani Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Vivani Medical	Positive
ABVC BioPharma	Neutral

ABVC BioPharma has higher revenue and earnings than Vivani Medical. ABVC BioPharma is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A
ABVC BioPharma	$510K	60.62	-$7.91M	-$0.30	N/A

6.8% of Vivani Medical shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 53.3% of Vivani Medical shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ABVC BioPharma's return on equity of -47.68% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-191.05%	-70.91%
ABVC BioPharma	N/A	-47.68%	-30.97%

Summary

Vivani Medical beats ABVC BioPharma on 8 of the 14 factors compared between the two stocks.

How does ABVC BioPharma compare to Aardvark Therapeutics?

ABVC BioPharma (NASDAQ:ABVC) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

ABVC BioPharma has higher revenue and earnings than Aardvark Therapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	60.62	-$7.91M	-$0.30	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

ABVC BioPharma has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.74, meaning that its share price is 274% more volatile than the broader market.

In the previous week, Aardvark Therapeutics had 23 more articles in the media than ABVC BioPharma. MarketBeat recorded 23 mentions for Aardvark Therapeutics and 0 mentions for ABVC BioPharma. Aardvark Therapeutics' average media sentiment score of 0.05 beat ABVC BioPharma's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ABVC BioPharma	Neutral
Aardvark Therapeutics	Neutral

Aardvark Therapeutics has a consensus price target of $15.33, suggesting a potential upside of 185.01%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42

11.4% of ABVC BioPharma shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ABVC BioPharma's return on equity of -47.68% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Aardvark Therapeutics	N/A	-71.54%	-64.94%

Summary

Aardvark Therapeutics beats ABVC BioPharma on 8 of the 15 factors compared between the two stocks.

How does ABVC BioPharma compare to Polaryx Therapeutics?

ABVC BioPharma (NASDAQ:ABVC) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

ABVC BioPharma has higher revenue and earnings than Polaryx Therapeutics. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	60.62	-$7.91M	-$0.30	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

11.4% of ABVC BioPharma shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Polaryx Therapeutics' return on equity of 0.00% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Polaryx Therapeutics	N/A	N/A	N/A

Polaryx Therapeutics has a consensus target price of $7.67, indicating a potential upside of 275.82%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Polaryx Therapeutics' average media sentiment score of 0.30 beat ABVC BioPharma's score of 0.00 indicating that Polaryx Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ABVC BioPharma	Neutral
Polaryx Therapeutics	Neutral

Summary

Polaryx Therapeutics beats ABVC BioPharma on 9 of the 13 factors compared between the two stocks.

How does ABVC BioPharma compare to Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cumberland Pharmaceuticals has a beta of 0.13, suggesting that its share price is 87% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

ABVC BioPharma has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
ABVC BioPharma	N/A	-47.68%	-30.97%

In the previous week, Cumberland Pharmaceuticals had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 2 mentions for Cumberland Pharmaceuticals and 0 mentions for ABVC BioPharma. Cumberland Pharmaceuticals' average media sentiment score of 0.25 beat ABVC BioPharma's score of 0.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cumberland Pharmaceuticals	Neutral
ABVC BioPharma	Neutral

Cumberland Pharmaceuticals has higher revenue and earnings than ABVC BioPharma. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.46	-$2.84M	-$0.71	N/A
ABVC BioPharma	$510K	60.62	-$7.91M	-$0.30	N/A

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cumberland Pharmaceuticals beats ABVC BioPharma on 8 of the 13 factors compared between the two stocks.

Get ABVC BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVC vs. The Competition

Export

Metric	ABVC BioPharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$30.92M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-3.87	792.21	274.93	25.38
Price / Sales	60.62	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	2.23	10.53	10.46	6.33
Net Income	-$7.91M	$2.82B	$3.49B	$358.33M
7 Day Performance	18.36%	1.69%	0.59%	1.12%
1 Month Performance	23.88%	0.83%	-2.01%	-2.67%
1 Year Performance	-59.15%	3.90%	18.09%	6.01%

ABVC BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVC ABVC BioPharma	0.1223 of 5 stars	$1.16 +0.9%	N/A	-57.4%	$30.92M	$510K	N/A	19
RFL Rafael	0.125 of 5 stars	$2.11 -1.4%	N/A	+29.4%	$111.28M	$920K	N/A	23	Short Interest Increase Gap Up
VANI Vivani Medical	3.3884 of 5 stars	$1.22 -0.8%	$3.75 +207.4%	-19.0%	$110.95M	N/A	N/A	36
AARD Aardvark Therapeutics	3.4334 of 5 stars	$5.15 +2.6%	$15.33 +197.7%	-52.3%	$109.86M	N/A	N/A	28	Trending News
PLYX Polaryx Therapeutics	3.0164 of 5 stars	$2.03 -1.0%	$7.67 +277.7%	N/A	$101.93M	N/A	N/A	11	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVC) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ABVC BioPharma (ABVC) Competitors

ABVC vs. RFL, VANI, AARD, PLYX, and CPIX

How does ABVC BioPharma compare to Rafael?

Summary

How does ABVC BioPharma compare to Vivani Medical?

Summary

How does ABVC BioPharma compare to Aardvark Therapeutics?

Summary

How does ABVC BioPharma compare to Polaryx Therapeutics?

Summary

How does ABVC BioPharma compare to Cumberland Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ABVC BioPharma (ABVC) Competitors

ABVC vs. RFL, VANI, AARD, PLYX, and CPIX

How does ABVC BioPharma compare to Rafael?

Is ABVC or RFL more profitable?

Which has better earnings and valuation, ABVC or RFL?

Do institutionals and insiders hold more shares of ABVC or RFL?

Which has more volatility and risk, ABVC or RFL?

Does the media prefer ABVC or RFL?

Do analysts prefer ABVC or RFL?

Summary

How does ABVC BioPharma compare to Vivani Medical?

Which has more volatility and risk, VANI or ABVC?

Do analysts rate VANI or ABVC?

Does the media favor VANI or ABVC?

Which has preferable earnings and valuation, VANI or ABVC?

Do institutionals & insiders hold more shares of VANI or ABVC?

Is VANI or ABVC more profitable?

Summary

How does ABVC BioPharma compare to Aardvark Therapeutics?

Which has higher earnings & valuation, ABVC or AARD?

Which has more volatility and risk, ABVC or AARD?

Does the media refer more to ABVC or AARD?

Do analysts prefer ABVC or AARD?

Do institutionals and insiders have more ownership in ABVC or AARD?

Is ABVC or AARD more profitable?

Summary

How does ABVC BioPharma compare to Polaryx Therapeutics?

Which has better valuation & earnings, ABVC or PLYX?

Do institutionals and insiders believe in ABVC or PLYX?

Is ABVC or PLYX more profitable?

Do analysts prefer ABVC or PLYX?

Does the media prefer ABVC or PLYX?

Summary

How does ABVC BioPharma compare to Cumberland Pharmaceuticals?

Do analysts rate CPIX or ABVC?

Which has more risk and volatility, CPIX or ABVC?

Is CPIX or ABVC more profitable?

Does the media prefer CPIX or ABVC?

Which has stronger earnings and valuation, CPIX or ABVC?

Do institutionals and insiders have more ownership in CPIX or ABVC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools